Terns Pharmaceuticals

From navigating a non-linear career path to becoming CEO, Amy Burroughs shares her unique journey to leading Terns in the latest Biotech2050 podcast episode.    In the episode, she reflects on the experiences that shaped her leadership, the importance of mentorship in developing the next generation of industry leaders, and how community collaboration drives meaningful innovation.    Amy also shares updates on Terns’ progress in bringing transformative medicines to people living with serious diseases, including advancements in our #oncology and #obesity programs. Listen here: https://lnkd.in/eTp4Tm7a

Innovation doesn’t happen in isolation. At Terns, collaboration across diverse teams and with external partners fuels our ability to push science forward. Whether it’s through industry forums, strategic partnerships, or cross-functional teamwork, we’re focused on building connections that accelerate progress and bring new possibilities to patients. This culture of collaboration is what drives our continued efforts in early-stage research and development. Learn more about how we work together: https://lnkd.in/d2cXYKC

At Terns, we’re focused on advancing science in cardiometabolic disease, where the need for new, thoughtfully developed treatment approaches remains high.    Last month at the American Diabetes Association’s Scientific Sessions (#ADA2025), we connected with researchers, clinicians, and industry leaders who share our commitment to making meaningful progress in this field. Topline data from our ongoing Phase 2 FALCON study, which recently completed enrollment and is designed to explore a novel approach in this area of unmet need, is expected in the fourth quarter of 2025.  Learn more about our work in cardiometabolic disease: https://lnkd.in/grjedH4    

Last month we attended #BIO2025, where we connected with industry leaders and potential collaborators across the #biotech ecosystem.    Terns is committed to expanding its approach to providing patients with global access to novel medicines. We explore collaborations with partners who share our vision and goals, and whose capabilities complement the strengths of our drug discovery and development team.    Learn more about our approach to partnerships: https://lnkd.in/eEJDJqNR  To connect with our team, reach out at BD@ternspharma.com  Brian Yip

At Terns, our people and culture are the foundation of everything we do. We strive to create a workplace where collaboration, respect, and growth are not just values but daily practices.    We believe that fostering an inclusive and supportive environment empowers our team to innovate and make a meaningful impact. It’s this commitment to our people that drives us forward as we work to bring transformative medicines to patients worldwide.    Learn more about who we are: https://lnkd.in/etpBzqj5 Nami Hoppin

#ICYMI: At the 30th European Hematology Association Congress (#EHA2025) last month, preclinical data from our chronic myeloid leukemia (CML) program was presented during an oral session focused on novel approaches to treatment.    We’re proud to contribute to this important scientific dialogue and remain focused on advancing potential new strategies for people living with serious hematologic diseases.

Terns is seeking a Clinical Scientist to support the design, execution, and analysis of early-stage clinical trials in oncology and metabolic disease. This role offers the opportunity to work cross-functionally in a fast-paced, science-driven environment. Join us in advancing innovative research that aims to make a meaningful impact for patients. Apply now: https://lnkd.in/guNHZf2

This week, members of the Terns team are in Boston for the Leerink Partners Therapeutics Forum: I&I and Metabolism. We're looking forward to engaging in meaningful conversations with investors and leaders in immunology, inflammation, and metabolic disease.

The International CML Foundation recently launched their Clinical Trial Hub, making it easier for patients, caregivers, and healthcare professionals to access timely information on clinical trials for chronic myeloid #leukemia (CML), including the CARDINAL trial.      As we continue to enroll patients in the CARDINAL clinical trial, we’re excited by initiatives like this that are helping connect the CML community with useful resources. Find up-to-date information on clinical trials here: https://lnkd.in/eFccFaqF   Debra Sieminski

It’s been a busy month at Terns, attending key industry conferences from #FiresideChats at the #JefferiesHealthcare, and the #GoldmanSachsHealthcare2025, to meeting 1x1 with peers at #BIO2025, to presenting data from our #oncology and #obesity development programs at #EHA2025 and #ADA2025.    We’re excited to build on these connections as we continue our efforts to drive meaningful progress for those living with serious diseases. Check out some highlights from the month!